16-Dec-2025
Bank of America Securities Sticks to Their Hold Rating for Idexx Laboratories (IDXX)
TipRanks (Mon, 15-Dec 7:25 AM ET)
IDEXX Laboratories Delivers Double-Digit Revenue and EPS Growth, Boosts Outlook for 2025
Market Chameleon (Mon, 3-Nov 6:16 AM ET)
IDEXX Laboratories Lifts 2025 Outlook as Diagnostics Drive Double-Digit Growth
Market Chameleon (Mon, 3-Nov 2:37 AM ET)
IDEXX Laboratories Announces Third Quarter Results
Business Wire (Mon, 3-Nov 6:30 AM ET)
Bonsai Health Names ModMed Veteran Rick Trefzger Chief Revenue Officer
Business Wire (Thu, 16-Oct 7:00 AM ET)
IDEXX Laboratories to Release 2025 Third Quarter Financial Results
Business Wire (Wed, 8-Oct 2:00 PM ET)
IDEXX Laboratories Elects Karen Peacock to Board of Directors
Business Wire (Tue, 7-Oct 7:00 AM ET)
IDEXX Stock Rockets 26.5% After Earnings—Can History Offer Clues to What Happens Next?
Market Chameleon (Mon, 4-Aug 7:40 AM ET)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Idexx Laboratories trades on the NASDAQ stock market under the symbol IDXX.
As of December 16, 2025, IDXX stock price declined to $693.18 with 657,457 million shares trading.
IDXX has a beta of 0.76, meaning it tends to be less sensitive to market movements. IDXX has a correlation of 0.15 to the broad based SPY ETF.
IDXX has a market cap of $56.17 billion. This is considered a Large Cap stock.
Last quarter Idexx Laboratories reported $1 billion in Revenue and $3.22 earnings per share. This beat revenue expectation by $34 million and exceeded earnings estimates by $.08.
In the last 3 years, IDXX traded as high as $769.98 and as low as $356.14.
The top ETF exchange traded funds that IDXX belongs to (by Net Assets): VTI, VOO, VO, QQQ, VUG.
IDXX has outperformed the market in the last year with a return of +61.0%, while the SPY ETF gained +13.1%. In the last 3 month period, IDXX beat the market returning +7.4%, while SPY returned +3.1%. However, in the most recent 2 weeks IDXX has underperformed the stock market by returning -5.4%, while SPY returned -0.4%.
IDXX support price is $686.68 and resistance is $714.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDXX shares will trade within this expected range on the day.